Company / R&D Expense
VYNE Therapeutics Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$30.9M
FY2025
5-year range
$16.3M / $43.5M
FY2021-FY2025
Trend
+89.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense returned to growth in FY2025 after 4 years of decline, reaching $31M.
Based on SEC 10-K filings.
$31M in FY2025 with a 5-year CAGR of -13.7%.
Improved from $18M to $31M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +16.6%
- 5-Year CAGR
- -13.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -13.7%, indicating a declining trend.
- In FY2025, r&d expense increased 89.8% year-over-year.
- Peak r&d expense was recorded in FY2020.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $30.9M | +89.8% |
| FY2024 | $16.3M | -11.3% |
| FY2023 | $18.4M | -5.9% |
| FY2022 | $19.5M | -55.1% |
| FY2021 | $43.5M | -32.5% |
| FY2020 | $64.5M | +122.3% |
| FY2019 | $29.0M | +157.7% |
| FY2018 | $11.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026